These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 33617042)
1. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. Kaul M; Jarvis P; Rozenberg I; Kolbinger F; Di Padova F; Calonder C; Espie P; Rondeau JM; Cebe R; Huber T; Mussmann R; Aassi M; Sligh TS J Eur Acad Dermatol Venereol; 2021 May; 35(5):1143-1151. PubMed ID: 33617042 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107 [TBL] [Abstract][Full Text] [Related]
3. Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne. Thiboutot DM; Craft N; Rissmann R; Gatlik E; Souquières M; Jones J; Loesche C J Dermatolog Treat; 2023 Dec; 34(1):2138691. PubMed ID: 36305633 [TBL] [Abstract][Full Text] [Related]
4. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114 [TBL] [Abstract][Full Text] [Related]
5. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. Nakagawa H; Niiro H; Ootaki K; J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109 [TBL] [Abstract][Full Text] [Related]
6. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969 [TBL] [Abstract][Full Text] [Related]
7. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829 [TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. Jiang C; Du Y; Liu X; Wang J; Ge C; Xu J; Wang S; Li B; Zhu G; Zhang W; Qian Q; Ma C; Zhu X; Zhan Y; Yang Y Br J Dermatol; 2023 Dec; 190(1):28-36. PubMed ID: 37669307 [TBL] [Abstract][Full Text] [Related]
9. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H; J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738 [TBL] [Abstract][Full Text] [Related]
10. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291 [TBL] [Abstract][Full Text] [Related]
11. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013 [TBL] [Abstract][Full Text] [Related]
12. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J; Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study. Wu NL; Hsu CJ; Sun FJ; Tsai TF J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369 [TBL] [Abstract][Full Text] [Related]
14. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257 [TBL] [Abstract][Full Text] [Related]
15. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE). Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677 [TBL] [Abstract][Full Text] [Related]
16. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study. Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466 [TBL] [Abstract][Full Text] [Related]
17. Secukinumab in plaque psoriasis--results of two phase 3 trials. Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ; N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392 [TBL] [Abstract][Full Text] [Related]